Aptus Pharma raises $4.77M in private placement
What's the deal? Aptus PharmaDealroom has a profile for this one. Try Dealroom → raised US$6.07M on November 12, 2026 through a private placement, allotting 15,97,470 equity shares at US$3.8 each to 188 investors. The Indian pharmaceutical company priced the shares at a US$3.67 premium over their US$0.14 face value.
Who's in? Backers include Ansh Cotton LLP, Halewood Laboratories Private Limited, and a group of individual investors such as Rameshchandra Dayarambhai Pujara and Yogesh Prafulchandra Tejani. The issue proceeded under SEBI's Issue of Capital and Disclosure Requirements Regulations, 2018.
Why now? The allotment completes a raise first proposed in August, approved by shareholders at the September 14 annual general meeting, and cleared by BSE Limited on October 30. The final issue came in 5,400 shares below the 16,02,870 approved, after one allottee withdrew and another did not subscribe.
What's the endgame? Aptus Pharma has said the money will fund manufacturing capacity and storage facilities, working capital, and broader expansion, including pan-India distribution and potential export markets. The raise lifted its paid-up equity capital from US$2.33M to US$2.55M.
By the numbers: The company reported H1 FY27 revenue of US$6.64M, already above its full FY26 figure of US$6.32M, with net profit of US$688.5K. Its model remains trading-heavy, with rising receivables and negative operating cash flow.
The signal: The raise is notable for a small, marketing-led drugmaker trying to build in-house manufacturing. It is not a sector-wide funding trend; its significance will hinge on whether the planned capacity and expansion translate into operating growth.
Read more: multibagg.ai
Image credit: Generated with Gemini
